Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorCHA University
About this trial
The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.
Eligibility criteria
Qualifiers
Patients with histologically or cytologically confirmed advanced biliary tract cancer.
Patients scheduled to receive Lenvatinib + Pembrolizumab for the treatment of advanced biliary tract cancer.
ECOG performance status of 0-2.
Patients aged 20 years or older at the time of treatment initiation.
Disqualifiers
Patients who do not consent to participate in the study or withdraw their consent.
Trial design
Treatments tested in this trial
- lenvatinib plus pembrolizumab
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov